Oxygen Biotherapeutics is a development stage biomedical company engaged in the development of oxygen-rich intravenous and topical products. Oxycyte, the company’s proprietary perfluorocarbon (PFC) therapeutic oxygen carrier, is currently in clinical and preclinical studies for intravenous delivery for various indications. Oxygen Biotherapeutics is also developing PFC-based creams and gels for topical skin delivery for dermatologic conditions and potentially for wound care, and the company has commercialized its Dermacyte skin care cosmetics line for the anti-aging market. For more information, visit the company’s Web site at www.oxybiomed.com.

The 6th Annual OneMedForum is a gathering of leading investors and management of some of the most promising emerging life science companies in Asia and North America. Through panels, workshops and up-close programming with top industry leaders, attendees explore strategies for company growth finance with healthcare investors looking for outsized returns. For more information, please visit www.onemedforum.com.

Let us hear your thoughts below: